Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: A double-targeted prodrug approach

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 624-632

  Sun, Jing ^a   Dahan, Arik ^b   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (HYDROXYMETHYL)PHENYL]GUANIDINE; AMINO ACID; ARGATROBAN; ENZYME; ESTER; GUANIDINE DERIVATIVE; ISOLEUCINE; ISOLEUCINE [3 (HYDROXYMETHYL)PHENYL]GUANIDINE; PEPTIDE TRANSPORTER 1; PHENYLALANINE; PHENYLALANINE [3 (HYDROXYMETHYL)PHENYL]GUANIDINE; PRODRUG ACTIVATING ENZYME; TRITIUM; UNCLASSIFIED DRUG; VALACICLOVIR; VALACYCLOVIRASE; VALINE; VALINE [3 (HYDROXYMETHYL)PHENYL]GUANIDINE; ZANAMIVIR;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSPORT; ENZYME ACTIVATION; HALF LIFE TIME; HELA CELL; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; ISOTOPE LABELING; MICHAELIS MENTEN KINETICS; MOLECULE; MONOLAYER CULTURE; NONHUMAN; RAT;

AMINO ACIDS; ANTIVIRAL AGENTS; CACO-2 CELLS; CARBOXYLIC ESTER HYDROLASES; DRUG DELIVERY SYSTEMS; ESTERS; GUANIDINES; HELA CELLS; HUMANS; INTESTINAL ABSORPTION; KINETICS; PRODRUGS; SYMPORTERS;

EID: 77249109864     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9011559     Document Type: Article

References (37)

1. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47 (10), 2393-2404.
2. Han, H. K.; Amidon, G. L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000, 2 (1), E6.
3. +/ peptide symporter PEPT1: structure-affinity relationships. Eur. J. Pharm. Sci. 2004, 21 (1), 53-60.
4. Daniel, H.; Kottra, G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004, 447 (5), 610-618.
5. Soul-Lawton, J.; Seaber, E.; On, N.; Wootton, R.; Rolan, P.; Posner, J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 1995, 39 (12), 2759-2764.
6. Balimane, P. V.; Tamai, I.; Guo, A.; Nakanishi, T.; Kitada, H.; Leibach, F. H.; Tsuji, A.; Sinko, P. J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250 (2), 246-251.
7. Jung, D.; Dorr, A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J. Clin. Pharmacol. 1999, 39 (8), 800-804.
8. Sugawara, M.; Huang, W.; Fei, Y. J.; Leibach, F. H.; Ganapathy, V.; Ganapathy, M. E. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 2000, 89 (6), 781-789.
9. Kim, I.; Chu, X. Y.; Kim, S.; Provoda, C. J.; Lee, K. D.; Amidon, G. L. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 2003, 278 (28), 25348-25356.
10. Li, F.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 2008, 97 (3), 1109-1134.
11. Han, H.; de Vrueh, R. L.; Rhie, J. K.; Covitz, K. M.; Smith, P. L.; Lee, C. P.; Oh, D. M.; Sadee, W.; Amidon, G. L. 50-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15 (8), 1154-1159.
12. Landowski, C. P.; Song, X.; Lorenzi, P. L.; Hilfinger, J. M.; Amidon, G. L. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm. Res. 2005, 22 (9), 1510-1518.
13. Landowski, C. P.; Vig, B. S.; Song, X.; Amidon, G. L. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol. Cancer Ther. 2005, 4 (4), 659-667.
14. Tsume, Y.; Vig, B. S.; Sun, J.; Landowski, C. P.; Hilfinger, J. M.; Ramachandran, C.; Amidon, G. L. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules 2008, 13 (7), 1441-1454.
15. Tsume, Y.; Hilfinger, J. M.; Amidon, G. L. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol. Pharm. 2008, 5 (5), 717-727.
16. Song, X.; Lorenzi, P. L.; Landowski, C. P.; Vig, B. S.; Hilfinger, J. M.; Amidon, G. L. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharm. 2005, 2 (2), 157-167.
17. Li, F.; Hong, L.; Mau, C. I.; Chan, R.; Hendricks, T.; Dvorak, C.; Yee, C.; Harris, J.; Alfredson, T. Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J. Pharm. Sci. 2006, 95 (6), 1318-1325.
18. Sun, Y.; Sun, J.; Shi, S.; Jing, Y.; Yin, S.; Chen, Y.; Li, G.; Xu, Y.; He, Z. Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Mol. Pharm. 2009, 6 (1), 315-325.
19. Kim, I.; Song, X.; Vig, B. S.; Mittal, S.; Shin, H. C.; Lorenzi, P. J.; Amidon, G. L. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol. Pharm. 2004, 1 (2), 117-127.
20. Nicklin, P.; Keates, A. C.; Page, T.; Bailey, C. J. Transfer of metformin across monolayers of human intestinal Caco-2 cells and across rat intestine. Int. J. Pharm. 1996, 128 (1-2), 155-162.
21. Zhou, M.; Xia, L.; Wang, J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab. Dispos. 2007, 35 (10), 1956-1962.
22. Bourdet, D. L.; Pritchard, J. B.; Thakker, D. R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 2005, 315 (3), 1288-1297.
23. Cass, L. M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 1999, 36 (Suppl. 1), 1-11.
24. Linkins, L. A.; Weitz, J. I. Pharmacology and clinical potential of direct thrombin inhibitors. Curr. Pharm. Des. 2005, 11 (30), 3877-3884.
25. Saulnier, M. G.; Frennesson, D. B.; Deshpande, M. S.; Hansel, S. B.; Vyas, D. M. An efficient method for the synthesis of guanidino prodrugs. Bioorg. Med. Chem. Lett. 1994, 4 (16), 1985-1990.
26. Humphreys, W. G.; Obermeier, M. T.; Chong, S.; Kimball, S. D.; Das, J.; Chen, P.; Moquin, R.; Han,W. C.; Gedamke, R.; White, R. E.; Morrison, R. A. Oxidative activation of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole. Xenobiotica 2003, 33 (1), 93-106.
27. Arafa, R. K.; Brun, R.; Wenzler, T.; Tanious, F. A.; Wilson, W. D.; Stephens, C. E.; Boykin, D. W. Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J. Med. Chem. 2005, 48 (17), 5480-5488.
28. Arafa, R. K.; Ismail, M. A.; Munde, M.; Wilson, W. D.; Wenzler, T.; Brun, R.; Boykin, D. W. Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents. Eur. J. Med. Chem. 2008, 43 (12), 2901-2908.
29. +/ peptide symporter. Eur. J. Biochem. 1999, 266 (2), 502-508.
30. Vig, B. S.; Stouch, T. R.; Timoszyk, J. K.; Quan, Y.; Wall, D. A.; Smith, R. L.; Faria, T. N. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. J. Med. Chem. 2006, 49 (12), 3636-3644.
31. Yang, X. D.; Ma, J. Y.; Barger, M. W.; Ma, J. K. Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages. Pharm. Res. 2002, 19 (6), 825-831.
32. +/peptide cotransporter PEPT1. J. Med. Chem. 2005, 48 (13), 4410-4419.
33. Lai, L.; Xu, Z.; Zhou, J.; Lee, K. D.; Amidon, G. L. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J. Biol. Chem. 2008, 283 (14), 9318-9327.
34. Hsu, C. P.; Hilfinger, J. M.; Walter, E.; Merkle, H. P.; Roessler, B. J.; Amidon, G. L. Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm. Res. 1998, 15 (9), 1376-1381.
35. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol. Pharm. 2006, 3 (6), 686-694.
36. Dahan, A.; Amidon, G. L. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297 (2), G371-377.
37. Dahan, A.; West, B. T.; Amidon, G. L. Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur. J. Pharm. Sci. 2009, 36 (2-3), 320-329.